Abstract:
Compounds having formula (I), and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein one of R and R is hydrogen, and the other of R and R is a group having formula (II), as well as pharmaceutically compositions containing such compounds and methods of immunomodulative therapy utilizing the same.
Abstract:
Oligopeptide compounds or oligopeptide analogue compounds of the formula A-B-D-E-G-J-L-M-Q are ligands for the anaphylatoxin receptor and are useful in the treatment of inflammatory disease states. Also disclosed are anaphylatoxin receptor ligand compositions and a method for modulating anaphylatoxin activity.
Abstract:
Compounds having the formula are useful for treating conditions which arise from or are exacerbated by angiogenesis. Also disclosed are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.
Abstract:
Compounds having formula (I), and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein one of R?104 and R105¿ is hydrogen, and the other of R?104 and R105¿ is a group having formula (II), as well as pharmaceutically compositions containing such compounds and methods of immunomodulative therapy utilizing the same.
Abstract:
Compounds having the formula are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
Abstract:
Immunomodulatory macrocylic compounds having the formula (VII) and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein X is selected from one of the formulae (Ia), (Ib) and (Ic), as well as pharmaceutical compositions containing the same.
Abstract:
Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed. Formula (I).
Abstract:
Compounds having methionine aminopeptidase-2 inhibitory (MetAP2) are described. Also described are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.
Abstract:
Compounds having the formula are methionine aminopeptidase type 2 (MetAP2) inhibitors and are useful for inhibiting angiogenesis. Also disclosed are MetAP2-inhibiting compositions and methods of inhibiting angiogenesis in a mammal.
Abstract:
The present invention relates to novel compounds of formula (I) which are useful as immunomodulators, in particular, macrolide immunosuppressants. The invention also relates to the preparation of compounds of formula (I), compositions containing such compounds, and methods of using such compounds.